Pell Bio-Med Technology's earnings have been declining at an average annual rate of -14.3%, while the Biotechs industry saw earnings growing at 21.8% annually. Revenues have been growing at an average rate of 18.3% per year.
How Pell Bio-Med Technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
TWSE:6949 Revenue, expenses and earnings (TWD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
26
-425
219
243
31 Dec 25
31
-424
210
253
30 Sep 25
30
-374
143
248
30 Jun 25
27
-356
137
238
31 Mar 25
27
-380
137
268
31 Dec 24
20
-389
135
266
30 Sep 24
18
-386
137
261
30 Jun 24
18
-404
148
256
31 Mar 24
18
-425
158
254
31 Dec 23
18
-399
145
240
30 Sep 23
20
-361
134
212
30 Jun 23
20
-310
115
187
31 Mar 23
19
-238
88
146
31 Dec 22
17
-230
82
143
31 Dec 21
14
-189
55
137
Quality Earnings: 6949 is currently unprofitable.
Growing Profit Margin: 6949 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6949 is unprofitable, and losses have increased over the past 5 years at a rate of 14.3% per year.
Accelerating Growth: Unable to compare 6949's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6949 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (12.2%).
Return on Equity
High ROE: 6949 has a negative Return on Equity (-15.83%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/28 21:49
End of Day Share Price
2026/06/26 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pell Bio-Med Technology Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.